GUANIDINE CARBONATE

US Previously Marketed

First approved in 1939

Details

Stereochemistry	ACHIRAL
Molecular Formula	2CH5N3.CH2O3
Molecular Weight	180.1658
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(N)=N.NC(N)=N.OC(O)=O

InChI

InChIKey=STIAPHVBRDNOAJ-UHFFFAOYSA-N

InChI=1S/2CH5N3.CH2O3/c3*2-1(3)4/h2*(H5,2,3,4);(H2,2,3,4)

HIDE SMILES / InChI

Molecular Formula	CH2O3
Molecular Weight	62.0248
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH5N3
Molecular Weight	59.0705
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593

Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated potassium channel 17 Target ID: CHEMBL2362996 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21926190	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Eaton-Lambert syndrome 5 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	Palliative		Approved 8583	GUANIDINE HYDROCHLORIDE Approved Use Guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis. Launch Date 1939

PubMed

Title	Date	PubMed
Presynaptic imidazoline receptors. New developments in characterization and classification.	1999 Jun 21	10415912
[The study of the Ca2+ role in cytotoxic response of human cells in culture to the action of xenobiotics].	2000	10752119
The picornavirus replication inhibitors HBB and guanidine in the echovirus-9 system: the significance of viral protein 2C.	2000 Apr	10725414
The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty.	2001	11311153
Topological diversity of artificial beta-barrels in water.	2001	11270328
Dihydrofolate reductase from Thermotoga maritima.	2001	11265474
Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 1. Conversion of 5-substituent on oxazolidinone.	2001 Apr	11310656
Total chemical synthesis of human matrix Gla protein.	2001 Apr	11274477
Strain-specified relative conformational stability of the scrapie prion protein.	2001 Apr	11274476
The structure of human mitochondrial branched-chain aminotransferase.	2001 Apr	11264579
High-sensitivity fluorescence anisotropy detection of protein-folding events: application to alpha-lactalbumin.	2001 Apr	11259312
Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent.	2001 Apr 12	11312922
Species-specific PCR for the identification of ovine, porcine and chicken species in meta and bone meal (MBM).	2001 Feb	11284433
Metric engineering of soft molecular host frameworks.	2001 Feb	11263869
[Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions].	2001 Feb	11218725
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.	2001 Feb	11168991
Uremic concentrations of guanidino compounds inhibit neutrophil superoxide production.	2001 Feb	11168990
Endogenous guanidino compounds as uremic neurotoxins.	2001 Feb	11168988
Molecular specificities of antibodies against ovine and murine recombinant prion proteins.	2001 Feb 16	11178966
Collision-induced dissociation of ring-opened cyclic depsipeptides with a guanidino group by electrospray ionization/ion trap mass spectrometry.	2001 Jan	11180644
Dichlorobis(glycocyamine-O)copper(II).	2001 Jan	11173378
Detection of enterovirus and hepatitis A virus RNA in mussels (Mytilus spp.) by reverse transcriptase-polymerase chain reaction.	2001 Jan	11155127
The relationship between visible intracellular aggregates that appear after overexpression of Sup35 and the yeast prion-like elements [PSI(+)] and [PIN(+)].	2001 Jan	11123686
Folding-unfolding of goat alpha-lactalbumin studied by stopped-flow circular dichroism and molecular dynamics simulations.	2001 Jan 1	11093260
Disulfide-dependent folding and export of Escherichia coli DsbC.	2001 Jan 12	11042167
Conformational origin of the aggregation of recombinant human factor VIII.	2001 Jan 16	11148054
The PD...(D/E)XK motif in restriction enzymes: a link between function and conformation.	2001 Jan 16	11148032
A kinetic folding intermediate probed by native state hydrogen exchange.	2001 Jan 19	11152615
Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp.	2001 Jan 23	11170394
Distributions of intramolecular distances in the reduced and denatured states of bovine pancreatic ribonuclease A. Folding initiation structures in the C-terminal portions of the reduced protein.	2001 Jan 9	11141061
[Antibody avidity: use for the diagnosis of HIV early infection].	2001 Jan-Feb	11174099
A rigid linker-scaffold for solid-phase synthesis of dimeric pharmacophores.	2001 Jan-Feb	11148071
Protein compactness measured by fluorescence resonance energy transfer. Human carbonic anhydrase ii is considerably expanded by the interaction of GroEL.	2001 Jun 15	11278767
alpha Arg-237 in Methylophilus methylotrophus (sp. W3A1) electron-transferring flavoprotein affords approximately 200-millivolt stabilization of the FAD anionic semiquinone and a kinetic block on full reduction to the dihydroquinone.	2001 Jun 8	11285259
Elucidation of a [4Fe-4S] cluster degradation pathway: rapid kinetic studies of the degradation of Chromatium vinosum HiPIP.	2001 Mar	11315562
Characterization of carbonic anhydrase from Neisseria gonorrhoeae.	2001 Mar	11248679
Cutinase unfolding and stabilization by trehalose and mannosylglycerate.	2001 Mar 1	11170208
The synthesis of beta-peptides containing guanidino groups.	2001 Mar 12	11266170
Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic.	2001 Mar 15	11277694
The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin.	2001 Mar 15	11238669
Structural alterations and inhibition of unisite and multisite ATP hydrolysis in soluble mitochondrial F1 by guanidinium chloride.	2001 Mar 20	11258961
Probing local conformational changes during equilibrium unfolding of firefly luciferase: fluorescence and circular dichroism studies of single tryptophan mutants.	2001 Mar 23	11263966
Dramatic stabilization of an SH3 domain by a single substitution: roles of the folded and unfolded states.	2001 Mar 30	11273710
The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.	2001 Mar 30	11266439
The structure of denatured alpha-lactalbumin elucidated by the technique of disulfide scrambling: fractionation of conformational isomers of alpha-lactalbumin.	2001 Mar 30	11118458
Cofactor-induced refolding: refolding of molten globule carbonic anhydrase induced by Zn(II) and Co(II).	2001 Mar 6	11258876
Osmolytes protect mitochondrial F(0)F(1)-ATPase complex against pressure inactivation.	2001 Mar 9	11257519
The dimerization of folded monomers of ribulose 1,5-bisphosphate carboxylase/oxygenase.	2001 Mar 9	11092881
Proton and metal ion-dependent assembly of a model diiron protein.	2001 May	11316876
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.	2001 May 15	11322922

Patents

Sample Use Guides

In Vivo Use Guide

Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.

Route of Administration: Oral

In Vitro Use Guide

Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:58:58 GMT 2025` Edited by `admin` on `Mon Mar 31 19:58:58 GMT 2025`
Record UNII	V3394X3G2W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-2171

Preferred Name

English

GUANIDINE CARBONATE

Official Name

English

CARBONIC ACID, COMPD. WITH GUANIDINE (1:2)

Common Name

English

DIGUANIDINIUM CARBONATE

Systematic Name

English

GUANIDINE CARBONATE (2:1)

Systematic Name

English

BISGUANIDINIUM CARBONATE

Systematic Name

English

GUANIDINIUM CARBONATE

Systematic Name

English

Code System Code Type Description

ECHA (EC/EINECS)

209-813-7